Payment overview · 2025
General Payments
$740.35
46 reported records · 14 companies
Healthcare provider profile · identity verified
Mary D Mitchell, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLORENCE, SC · NPI 1215041058
Verified facts
What the public records show
CMS Open Payments records show Mary D Mitchell, FNP received $740.35 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $212.98 | 28.8% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.10 | 18.2% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.03 | 9.9% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $44.36 | 6.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.08 | 6.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.86 | 5.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.06 | 4.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $29.91 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.58 | 3.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.30 | 3.8% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.60 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.82 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.01 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.66 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $740.35 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.32 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.37 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.66 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.11 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.73 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $44.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.08 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.08 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.58 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 781 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 128 |
| Gabapentin | Gabapentin | 365 | 77 |
| Losartan Potassium | Losartan Potassium | 349 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 332 | 86 |
| Pravastatin Sodium | Pravastatin Sodium | 322 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 52 |
| Furosemide | Furosemide | 239 | 67 |
| Metformin Hcl | Metformin Hcl | 235 | 61 |
| Omeprazole | Omeprazole | 217 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 36 |
| Montelukast Sodium | Montelukast Sodium | 144 | 30 |
| Potassium Chloride | Potassium Chloride | 139 | 30 |
| Lisinopril | Lisinopril | 138 | 31 |
| Carvedilol | Carvedilol | 137 | 34 |
| Metformin Hcl Er | Metformin Hcl | 130 | 32 |
| Famotidine | Famotidine | 116 | 29 |
| Spironolactone | Spironolactone | 115 | 33 |
| Eliquis | Apixaban | 112 | 20 |
| Alendronate Sodium | Alendronate Sodium | 106 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 34 |
| Celecoxib | Celecoxib | 102 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 26 |
| Irbesartan | Irbesartan | 87 | 16 |
| Meloxicam | Meloxicam | 84 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 24 |
| Nifedipine Er | Nifedipine | 80 | 19 |
| Jardiance | Empagliflozin | 78 | 13 |
| Trazodone Hcl | Trazodone Hcl | 78 | 16 |
| Prednisone | Prednisone | 75 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 12 |
| Linzess | Linaclotide | 70 | 17 |
| Trulicity | Dulaglutide | 67 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 14 |
| Meclizine Hcl | Meclizine Hcl | 65 | 17 |
| Ibuprofen | Ibuprofen | 64 | 23 |
| Tramadol Hcl | Tramadol Hcl | 64 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 15 |
| Lovastatin | Lovastatin | 62 | 16 |
| Allopurinol | Allopurinol | 61 | 11 |
| Baclofen | Baclofen | 60 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 39 |
| Levetiracetam | Levetiracetam | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 13 |
| Verapamil Er | Verapamil Hcl | 42 | 12 |
| Farxiga | Dapagliflozin Propanediol | 41 | 12 |
| Ozempic | Semaglutide | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 11 |
| Glipizide | Glipizide | 39 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Azithromycin | Azithromycin | 28 | 27 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Fluconazole | Fluconazole | 25 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $740.35 · 46 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, CREON, GARDASIL 9, IBSRELA, LINZESS, MOUNJARO, OTEZLA, Ozempic, QULIPTA, QUTENZA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error